Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer

References

• Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28(2):256–263. doi:10.1200/JCO.2009.23.9194.
   PubMed Web of Science ®Google Scholar
• Choi MS, Huh JW, Shin JK, Park YA, Cho YB, Kim HC, et al. Prognostic factors and treatment of recurrence after local excision of rectal cancer. Yonsei Med J. 2021; 62(12):1107–1116. doi:10.3349/ymj.2021.62.12.1107.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(3):329–359. doi:10.6004/jnccn.2021.0012.
   PubMed Web of Science ®Google Scholar
• Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–1482. doi:10.1016/s0140-6736(86)91510-2.
   PubMed Web of Science ®Google Scholar
• Song JH, Jeong JU, Lee JH, Kim SH, Cho HM, Um JW, Jang HS, Korean Clinical Practice Guideline for Colon and Rectal Cancer Committee. Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II-III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol J. 2017;35(3):198–207. doi:10.3857/roj.2017.00059.
   PubMedGoogle Scholar
• Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–1933. doi:10.1200/JCO.2011.40.1836.
   PubMed Web of Science ®Google Scholar
• Lee BC, Park IJ, Kim CW, Lim SB, Yu CS, Kim JC. Matched case-control analysis comparing oncologic outcomes between preoperative and postoperative chemoradiotherapy for rectal cancer. Ann Surg Treat Res. 2017; 92(4):200–207. doi:10.4174/astr.2017.92.4.200.
   PubMed Web of Science ®Google Scholar
• Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–928. doi:10.1002/bjs.8702.
   PubMed Web of Science ®Google Scholar
• Bahadoer RR, Dijkstra EA, van Etten B, Marijnen C, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42. doi:10.1016/S1470-2045(20)30555-6.
   PubMed Web of Science ®Google Scholar
• Chin RI, Roy A, Pedersen KS, Huang Y, Hunt SR, Glasgow SC, et al. Clinical complete response in patients with rectal adenocarcinoma treated with short-course radiation therapy and nonoperative management. Int J Radiat Oncol Biol Phys. 2022;112(3):715–725. doi:10.1016/j.ijrobp.2021.10.004.
   PubMed Web of Science ®Google Scholar
• Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37(34):3223–3233. doi:10.1200/JCO.18.02309.
   PubMed Web of Science ®Google Scholar
• Jidong Z, Ning J, Kaidong L. Evaluation of the efficacy of preoperative intensity-modulated radiotherapy combined with concurrent chemotherapy in locally advanced rectal cancer. Cancer Res Clin Pract. 2018; 30(6):391–395.
   Google Scholar
• Glimelius B, Tiret E, Cervantes A, Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 (Suppl 6):i81–i88.
   Web of Science ®Google Scholar
• van der Valk M, Hilling DE, Bastiaannet E, Meershoek-Klein KE, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–2545. doi:10.1016/S0140-6736(18)31078-X.
   PubMed Web of Science ®Google Scholar
• Akgun E, Caliskan C, Bozbiyik O, Yoldas T, Sezak M, Ozkok S, et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2018;105(11):1417–1425. doi:10.1002/bjs.10984.
   PubMed Web of Science ®Google Scholar
• Terzi C, Bingul M, Arslan NC, Ozturk E, Canda AE, Isik O, et al. Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. Colorectal Dis. 2020;22(3):279–288. doi:10.1111/codi.14867.
   PubMed Web of Science ®Google Scholar
• Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34(31):3773–3780. doi:10.1200/JCO.2016.67.6049.
   PubMed Web of Science ®Google Scholar
• Lefèvre JH, Mineur L, Cachanado M, Denost Q, Rouanet P, de Chaisemartin C, et al. Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer?: three years’ follow-up results of the Greccar-6 randomized multicenter trial. Ann Surg. 2019;270(5):747–754. doi:10.1097/SLA.0000000000003530.
   PubMed Web of Science ®Google Scholar
• Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336–346. doi:10.1016/S1470-2045(17)30086-4.
   PubMed Web of Science ®Google Scholar
• Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–842. doi:10.1093/annonc/mdw062.
   PubMed Web of Science ®Google Scholar